What question did this study set out to answer?

Evaluate the efficacy and safety of JNJ-55308942 in treating bipolar depression in outpatients.

Efficacy and safety of the selective, brain-penetrant P2X7 receptor antagonist JNJ-55308942 (zanvipixant) in bipolar depression: Phase 2a study

View Full Paper

Ask AI

Bookmark

Authors

Phase 2a trial evaluates the P2X7 receptor antagonist's efficacy in bipolar depression, suggesting further investigation is needed.

Evaluate the efficacy and safety of JNJ-55308942 in treating bipolar depression in outpatients.
Double-blind, placebo-controlled clinical trial
Participants aged 18-64 with bipolar disorder Types I/II
Randomized to receive either JNJ-55308942 or placebo
Primary endpoint measured using MADRS total score at Week 6
Adverse events monitored and compared between groups.
MADRS score change at Week 6 was -16.0 for JNJ-55308942 and -15.4 for placebo.
No statistically significant difference was found in the primary endpoint with a mean difference of -0.3.
Secondary findings showed a meaningful change in social functioning scores for the treatment group.
Adverse events were generally mild or moderate, with no clear group differences.

Palmer et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark